Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue remained firm both in Japan and overseas. Sales of immunoserological testing reagents increased, including fecal occult blood testing reagents for overseas markets and products introduced and sold through TOSOH CORPORATION. On the earnings side, operating income and ordinary income decreased due to fluctuations in overseas markets following the closure of USAID and changes in the sales mix, while net income increased due to an extraordinary gain on the transfer of equity interests in a consolidated subsidiary.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥41,899 million (YoY +3.4%) |
| Operating profit | ¥2,919 million (YoY -2.7%) |
| Ordinary income | ¥2,844 million (YoY -11.1%) |
| Profit attributable to owners of the parent | ¥3,708 million (YoY +66.5%) |
| Net income per share | ¥112.52 |
| Operating Margin | Current fiscal year 7 % / Previous period 7.4 % |
| Equity ratio | End of the current fiscal period 70.1 % / End of previous period 69.3 % |
| Total assets | ¥62,657 million |
| Net assets | ¥44,034 million |
| Cash flows from operating activities | ¥4,045 million |
| Cash flows from investing activities | ¥-3,423 million |
| Cash flows from financing activities | ¥-322 million |
| Cash and cash equivalents at end of period | ¥7,943 million |
| Full-year earnings forecast | Net Sales ¥42,000 million (YoY +0.2%) / Operating profit ¥3,070 million (YoY +5.2%) / Ordinary income ¥2,900 million (YoY +2.0%) / Net income ¥2,070 million (YoY -44.2%) |
| Annual Dividend Forecast | ¥58 → ¥58（0.0%） |
| Payout ratio | Current fiscal year 51.5 % / Next-year forecast 92.2 % |
| Shareholder Return Policy | Target a total payout ratio of at least 50% |
| Regional sales | Region Overseas / Net Sales ¥11,457 million / yoy_pct 7 |
| Depreciation and amortization | ¥2,536 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥8 million, Gain on transfer of investments in affiliates ¥2,004 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥22 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 栄研医薬(上海)有限公司 / Excluded Number of companies 1 / Company name 栄研生物科技（中国）有限公司 |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 34,541,438 shares |
| Treasury Shares at Period-End | 1,575,865 treasury shares |
| Factors Behind Changes in Business Performance | Revenue remained firm both in Japan and overseas. Sales of immunoserological testing reagents increased, including fecal occult blood testing reagents for overseas markets and products introduced and sold through TOSOH CORPORATION. On the earnings side, operating income and ordinary income decreased due to fluctuations in overseas markets following the closure of USAID and changes in the sales mix, while net income increased due to an extraordinary gain on the transfer of equity interests in a consolidated subsidiary. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue remained firm both in Japan and overseas. Operating income and ordinary income decreased due to fluctuations in overseas markets following the closure of USAID and changes in the sales mix, among other factors. Net income attributable to owners of the parent increased due to the recognition of an extraordinary gain on the transfer of equity interests in a consolidated subsidiary. For the next fiscal year, the Company expects sales of fecal occult blood testing reagents in overseas markets to increase and initiatives to improve profitability to progress, while net income is expected to decrease due to the reversal of the extraordinary gain recognized in the previous fiscal year.